Cargando…
Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults
The treatment of inflammatory arthritis has been revolutionised by the introduction of biologic treatments. Many biologic agents are currently licensed for use in both paediatric and adult patients with inflammatory arthritis and contribute to improved disease outcomes compared with the pre-biologic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212384/ https://www.ncbi.nlm.nih.gov/pubmed/34188697 http://dx.doi.org/10.1177/1759720X211002685 |
_version_ | 1783709631038619648 |
---|---|
author | Parikh, Chinar R. Ponnampalam, Jaya K. Seligmann, George Coelewij, Leda Pineda-Torra, Ines Jury, Elizabeth C. Ciurtin, Coziana |
author_facet | Parikh, Chinar R. Ponnampalam, Jaya K. Seligmann, George Coelewij, Leda Pineda-Torra, Ines Jury, Elizabeth C. Ciurtin, Coziana |
author_sort | Parikh, Chinar R. |
collection | PubMed |
description | The treatment of inflammatory arthritis has been revolutionised by the introduction of biologic treatments. Many biologic agents are currently licensed for use in both paediatric and adult patients with inflammatory arthritis and contribute to improved disease outcomes compared with the pre-biologic era. However, immunogenicity to biologic agents, characterised by an immune reaction leading to the production of anti-drug antibodies (ADAs), can negatively impact the therapeutic efficacy of biologic drugs and induce side effects to treatment. This review explores for the first time the impact of immunogenicity against all licensed biologic treatments currently used in inflammatory arthritis across age, and will examine any significant differences between ADA prevalence, titres and timing of development, as well as ADA impact on therapeutic drug levels, clinical efficacy and side effects between paediatric and adult patients. In addition, we will investigate factors associated with differences in immunogenicity across biologic agents used in inflammatory arthritis, and their potential therapeutic implications. |
format | Online Article Text |
id | pubmed-8212384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82123842021-06-28 Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults Parikh, Chinar R. Ponnampalam, Jaya K. Seligmann, George Coelewij, Leda Pineda-Torra, Ines Jury, Elizabeth C. Ciurtin, Coziana Ther Adv Musculoskelet Dis Review The treatment of inflammatory arthritis has been revolutionised by the introduction of biologic treatments. Many biologic agents are currently licensed for use in both paediatric and adult patients with inflammatory arthritis and contribute to improved disease outcomes compared with the pre-biologic era. However, immunogenicity to biologic agents, characterised by an immune reaction leading to the production of anti-drug antibodies (ADAs), can negatively impact the therapeutic efficacy of biologic drugs and induce side effects to treatment. This review explores for the first time the impact of immunogenicity against all licensed biologic treatments currently used in inflammatory arthritis across age, and will examine any significant differences between ADA prevalence, titres and timing of development, as well as ADA impact on therapeutic drug levels, clinical efficacy and side effects between paediatric and adult patients. In addition, we will investigate factors associated with differences in immunogenicity across biologic agents used in inflammatory arthritis, and their potential therapeutic implications. SAGE Publications 2021-06-16 /pmc/articles/PMC8212384/ /pubmed/34188697 http://dx.doi.org/10.1177/1759720X211002685 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Parikh, Chinar R. Ponnampalam, Jaya K. Seligmann, George Coelewij, Leda Pineda-Torra, Ines Jury, Elizabeth C. Ciurtin, Coziana Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults |
title | Impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults |
title_full | Impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults |
title_fullStr | Impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults |
title_full_unstemmed | Impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults |
title_short | Impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults |
title_sort | impact of immunogenicity on clinical efficacy and toxicity profile of
biologic agents used for treatment of inflammatory arthritis in children
compared to adults |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212384/ https://www.ncbi.nlm.nih.gov/pubmed/34188697 http://dx.doi.org/10.1177/1759720X211002685 |
work_keys_str_mv | AT parikhchinarr impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults AT ponnampalamjayak impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults AT seligmanngeorge impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults AT coelewijleda impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults AT pinedatorraines impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults AT juryelizabethc impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults AT ciurtincoziana impactofimmunogenicityonclinicalefficacyandtoxicityprofileofbiologicagentsusedfortreatmentofinflammatoryarthritisinchildrencomparedtoadults |